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Abstract
Purpose Health care requirements and perception of people with differences of sex development (DSD) have changed
enormously since the “Chicago Consensus Conference” in 2005. Therefore, new standards of care and evaluation of care
have to be developed.
Methods We summarize the social and legal approach to care for DSD during the last two decades and report the main
results of European research activities.
Results The last two decades were accompanied by legal and societal discussion regarding how to deal with a nonbinary
concept of sex. This leads to the necessity to assess health care requirements for individuals with DSD in an objective
manner. We briefly review the results of the recently funded European research projects dealing with health-related issues in
DSD like EU COST Action DSD, I-DSD, and dsd-LIFE, and address the compilation of quality indicators that will be
needed to benchmark health care provision and health care-related outcomes.
Conclusions The benchmarking process has to be implemented among health care providers for individuals with DSD
within the European Reference Networks for Rare Conditions.
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Introduction
Differences/disorders of sex development (DSD) describe
congenital conditions affecting sex development with a
broad spectrum of clinical, genetic, and laboratory findings
[1]. In the last decades, DSDs have undergone enormous
changes in general and medical perception, as well as
societal acceptance and medical care [2]. In this paper, we
will outline, how the increasing demand from people with
DSD, but also from health care professionals and the gen-
eral public has changed established clinical practices for the
management of patients within the health care systems
[3, 4]. In 2005, an international consensus conference was
held, which received wide acceptance for its change in
nomenclature and advice for management of the conditions
[1]. This new terminology and classification have given a
scientific basis for biological perception and have promoted
research both in the pathophysiological understanding as
well as in health services research for DSD. At the same
time discussions with patient organizations and public
debate have triggered claims for further actions that could
enhance acceptance of the conditions and decrease societal
taboo.
One reason for the ongoing discussion about how to deal
with DSD could be that “sex/gender” is not just one of
many equal value categories, but rather one that is of
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particular relevance not only for the individual but also for
society [5]. At the individual level, sex/gender is one of the
key elements of identity, self-image and sexuality and
potential fertility. In relation to all of these very intimate
aspects of personality, humans are extremely sensitive and
vulnerable. In addition to the individual meaning, gender
role, sexuality, and reproduction are aspects of human
beings that are subject to strong social regulation in all
cultures and times [6]. This is one of the classic areas of
negotiation between individual self-realization and personal
freedom, as well as social norms and controls.
Nowadays the initially used term “disorder of sex
development” has been exchanged by “differences of sex
development”, in order to challenge the traditionally binary
concept of sex and avoid socially inappropriate language
[7]. The negative notion of disorder has been changed to the
neutral term differences to strengthen and empower people
to live with the social and societal aspects of DSD.
Nevertheless, people with DSD will need entry into the
medical system for various reasons including confirmation
of diagnosis, thorough information about their condition as
well as appropriate care of eventual medical and psycho-
social consequences of the conditions [4, 8, 9]. At this time,
we have to assess the needs of patients with DSD in our
health care systems, benchmark the quality of care that is
delivered at specialized centers of care, and analyze effects
on patient care and health-related quality of life.
Needs for changing health care in DSD
DSD is an umbrella term for a large number of conditions
that affect sex development; they are classified as “rare
diseases” [1, 2, 10]. From a medical point of view only few
forms of DSD require acute medical action. Nevertheless,
there is a need for medical treatment in many respects,
which, however, can vary greatly depending on the diag-
nosis, age, and personal needs [3]. First and foremost,
medicine has the task of confirming a diagnosis and ana-
lyzing possible consequences of the variant gender devel-
opment (e.g., comorbidities, hormonal peculiarities). Other
areas in which medicine plays an important role for people
with DSD are pubertal development and sexual maturation,
mental health, sexual health, and fertility [3, 11].
Addressing the medical needs of people with DSD has
long been characterized by adjusting the individual to the
traditionally binary social sex/ gender norm (also surgically)
[1, 5, 12]. Over the last 50 years, this approach has been
increasingly criticized, when DSD-advocacy groups
denounced the poor outcomes of medical and psychological
care and demanded the right of intersex people to self-
determination, bodily integrity, and protection from dis-
crimination [13, 14]. In particular, children’s rights—and
here the right to an open future, in which they can later
determine their own gender and the associated protection
against “cosmetic” interventions—came into focus [15, 16].
The demands of these groups can be found in the context of
other empowerment movements, which, for example,
advocate the enforcement of patient rights (shared decision
making, informed consent, patient centered outcomes, e.g.),
and are based on the implementation of child and minority
rights [17, 18].
As a consequence, a change of perspective has occurred
in some legal systems. In the European Union DSD issues
have progressively emerged as being relevant to funda-
mental rights protection. For example, in 2012 the German
Ethics Council (Ethikrat) published a comprehensive opi-
nion on intersex issues, providing a range of recommen-
dations to safeguard the rights of intersex people [19]. A
challenge in changing legal frameworks is to consider the
latest ethical, psychological, sociological, and medical
findings wherever possible and to reflect each case on its
own merits [20]. In view of the complexity, the changes at
the legal level were implemented as an amendment to the
German Civil Status Act in December 2018 [21]. In addi-
tion to the previous binary or non-registration of the sex
entry, the act now also allows people with DSD in Germany
to use the third category “diverse” instead of “male” and
“female” and provides for facilitating regulations for
changes in the birth register (§§ 45 b, 22 para. 3 PStG). The
“diverse” category can also be applied in adult people with
DSD. In the meantime, there have also been changes in
many other countries of the EU and outside. In February
2019, the European Parliament adopted a landmark reso-
lution on the “Rights of Intersex People” [18]. Thereby the
European Parliament sets a clear standard within the Eur-
opean Union for the protection of intersex people’s body
integrity and human rights. The resolution complements the
2017 resolution “Promoting the human rights of and elim-
inating discrimination against intersex people” adopted by
the Parliamentary Assembly of the Council of Europe [22].
European research activities
Following the 2005 Consensus Workshop that stressed the
need for the regular collection and sharing of data across
geographical boundaries, a concerted effort through funding
from the European Society for Paediatric Endocrinology, an
EUFP7 grant and subsequently the MRC UK, led to the
development of the ESPE DSD Registry, which was suc-
ceeded by the European DSD Registry and subsequently the
I-DSD Registry [23]. With allied projects such as the EU
COST Action DSDnet, the FP7 project DSD-Life, the I-
DSD Registry and its allied registry, I-CAH, has not only
supported research activities but also paved the way to the
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benchmarking of services [3, 24]. Audit of clinical activity,
including patient reported experience measures, participat-
ing in disease registries, building collaborative working
partnerships, attendance at joint clinics and education
events are crucial if knowledge and information sharing is
to be optimized across clinical teams [25]. There is a need
for dedicated time for overseeing and/or performing these
tasks that allow structured management as well as audit of a
complex service, which would exemplify the center’s
commitment to quality assurance [8]. In this context, a clear
example where joint collaborative activities have the
potential to lead to an improvement in care quality is the
model of the European Reference Networks (ERN) that
have been funded by the EC for improving the care of
people with rare conditions [26]. There are at least two
ERNs, Endo-ERN and eUROGEN, which consist of refer-
ence centers for managing the care of people with condi-
tions associated with DSD. The challenge for these ERNs is
to show that their creation has led to an improvement in care
and for this, there is a clear need to measure and compare
easily collected indicators of care quality through projects
such as EuRRECa [27].
Measuring the quality of health care:
development of quality indicators for the
care of people with DSD
Health care needs assessment is based on three elements: (1)
existence of a nontrivial health risk or disorder (e.g., to be
graded on severity and prognosis); (2) potential availability
of, and access to services, and (3) patient’s ability to benefit
from services [28]. In DSD, the ability to benefit from
health care services is less well studied and there is scarce
evidence on the efficacy of therapies which is also due to
the difficulty of studying an extremely heterogenous and in
the specific diagnoses rare condition [1, 2].
The subjective and objective appraisal of the quality of
care people receive includes measurement of satisfaction
with services [9, 29]. Variations in treatment processes are
expected to be associated with patient reported outcomes
(PRO) related to patients’ satisfaction with care. Describing
components of care requires their systematic identification
and operationalization.
In general, quality indicators address relevant and mea-
surable aspects of care and indirectly depict the quality of a
unit through numbers or numerical ratios [28]. Evaluation
of health care quality in DSD is difficult, because there is no
gold standard for guideline-compliant and quality-assured
treatment processes and structural components of health
care institutions. To develop quality indicators, one relies on
the Donabedian model, with structure, process, and result
quality as central, interdependent quality dimensions in
health care [30]. Structural quality is defined as the
description of the framework conditions such as equipment,
availability and quality of laboratories, qualification of
personnel, formal training of teams, physical accessibility
for patients and other aspects that assess structural attributes
of the institution. The quality of the process relates to the
way in which the service is provided and describes all
activities that are carried out in the course of the individual
care in DSD, e.g., multiprofessional conferences, shared
decision making, quality of physician patient communica-
tion, waiting times, patient orientation, the process of
obtainment of informed consent, or the delivery of therapies
such as hormonal or fertility treatment. The quality of the
process is usually assessed from the patients’ perspective,
i.e., measuring satisfaction with care [31]. The quality of the
results focusses on treatment outcomes collected through
subjective assessment of the patient (e.g., quality of life)
and medical data, such as complication rates and standar-
dized evaluation of functionality. To ensure good structural
or process quality in DSD, the starting point in developing
quality indicators is to research the available national and
international guidelines and operationalize the recommen-
dations identified there [28, 32]. In addition, an extensive
literature search is necessary to identify further aspects that
are named as decisive for good care in DSD. Finally,
background information and references to other relevant
aspects with regard to quality of care have to be collected
through qualitative interviews with relevant stakeholders in
the field of DSD, such as medical expert team members,
affected individuals and self-organizations.
Indicators for the structural and process quality of care
must meet main criteria: relevance, sensitivity, specificity,
reliability, operational feasibility, and practicability [32]. A
first pilot assessment is used to check an initial set of
indicators with regard to feasibility and performance of each
indicator. Static analyses of floor and ceiling effects are
carried out and “underperforming” indicators are elimi-
nated. Well-performing indicators build the set of quality
indicators for further assessment. National guidelines and
expert opinions may influence the chosen set of quality
indicators, which can therefore differ between countries.
Examples of measuring the quality of care:
assessing the needs for health care of people
with DSD
Among standardized instruments to assess satisfaction with
care, the international customer satisfaction questionnaire
(CSQ-8) [33] and the Child/Youth Health Care-Satisfaction,
Utilization and Needs (C/YHC-SUN) [34, 35] have been
used in the population with DSD. The CSQ-8 is a self-report
questionnaire with eight items constructed to measure
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satisfaction with services in general [33], of which two
shortened versions (CSQ-3, CSQ-4) exist [36]. Primarily for
children and adolescents with chronic conditions, the long
and short version of the CHC-SUN [34] and the YHC-SUN
[35] were developed and later adapted for adults [29]. The
instruments consist of items in respect to provision, utiliza-
tion, access problems, and satisfaction with general practi-
tioner, specialist care, prescribed medicine, and emergency
services. Furthermore, unmet needs are assessed in 16 ser-
vices and can be adapted due to the evaluated health care
setting. Further items are related to satisfaction with care in
the last 12 months and comprise six domains “diagnosis/
information”, “coordination”, “child-(patient-)-centered
care”, “hospital (clinic) environment”, “doctors’ behavior”,
and “school related services” as well as a single item on
“general satisfaction with health care”.
One national study, called German network study [37],
and one European study, dsd-LIFE, [38] evaluated the
needs for health care of people with DSD. In the German
network study between 2005 and 2007, a total of 439
children, adolescents and adults with DSD were asked about
their satisfaction with specialist care [37]. In adults, the
greatest satisfaction with the specialist care was reported by
women with CAH, the lowest by participants with 46,XY
DSD and very rare DSDs [9]. In children, parents of girls
with CAH also reported greater satisfaction with specialist
treatment compared to other diagnostic groups. Satisfaction
was lowest among parents of children with 46,XY DSD
who grew up as a male; in particular, dissatisfaction with
the diagnostic process was high [39]. Regarding unmet
needs, the need for psychosocial support was reported by
more than half of the parents with children with 46,XY
DSD; but only half who stated a need had received a cor-
responding psychosocial care [40]. More than one decade
ago, this national study demonstrated the need for
improvement in the diagnostic process and for inclusion of
psychosocial care into the treatment of people with DSD.
In the European study dsd-LIFE, 1040 young people and
adults with DSD as described in the classification system of
the Chicago Consensus Conference took part in 2014/2015
[38]. Dsd-LIFE consisted of two study parts, one included a
medical interview, a retrospective chart review and medical
examinations following standard operation procedures, the
other one a PRO questionnaire. The PRO included socio-
demographic data standardized questionnaires about the
general quality of life, psychological well-being, psycho-
sexual development, sexuality and condition specific self-
constructed items as well as satisfaction with health care
(CSQ-4; YHC-SUN-SF) [33, 35]. Within the European
study, a center score was developed for the level of multi-
disciplinary care in each center for each diagnosis group
based on the criteria of the European Reference Network on
Rare Endocrine Conditions (Endo-ERN) [29]. This score
comprised the infrastructure at the hospital level (size of the
center, acknowledgment as a center of reference, partici-
pation in registries, national or international collaborations,
participation in clinical trials, access to molecular genetic
testing), infrastructure at the clinic level (team-size, options
for referrals) and the service delivery (availability of case
management, transitional care, collaboration with patient
organizations, conduct of case conferences, access to edu-
cational materials for patients, telephone counseling). Par-
ticipants with CAH and Turner syndrome reported a
tendency toward higher satisfaction with health care with
only small differences overall between the diagnostic
groups. However, it was clearly shown that a higher level of
multidisciplinary care in a center (higher “center score”)
was associated with a higher level of satisfaction. This was
true for all four diagnosis groups, but especially for all
participants who self-reported a good to very good health
status. This finding is even more important because across
all conditions, health status explained most of the variance
in quality of life [41]. In addition, this European study
revealed the need to decrease variability between centers of
reference/competence, especially in endocrine and fertility
treatment [11, 42]. The impact of care should not be
assessed only on patient satisfaction with care but also on
patient health outcomes like the general health status, which
is often not related to the condition itself but classified as
co-morbidity [43] or the mental health [44]. These findings
have major impact on the organization of care. Individuals
with DSD need both highly specialized care as well as a
coordinating medical center, addressing all issues of health
and collaborating with subspecialists.
Discussion and outlook
Research aiming to maintain or improve people’s health
includes basic science research, clinical studies evaluating
the effect of novel medical interventions on health out-
comes, including body structures and functions, physical
and mental performance, and quality of life. However,
health services research includes determinants other than
individual physical and mental health characteristics but
environmental factors such as the health care patients
receive. This is important to study because these determi-
nants are amendable to change and improvement in quality
of care may result in better health. Beyond quantitative
empirical data on the association of aspects of structural and
process quality, projects should include qualitative empiri-
cal data from both interviews with individuals and group
discussions (focus groups). Meaningful interpretation of
empirical data must be developed jointly with people
affected by DSD. Any project embarking on the study of
quality of care should develop a participatory research
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design including a wide variety of age groups and clinical
conditions. The emerging advocacy groups and self-
organizations have been an important source to clarify the
importance and appropriateness of measurements.
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of health care services and satisfaction with care in adults affected
by disorders of sex development (DSD). J. Gen. Intern. Med. 29,
752–759 (2014). https://doi.org/10.1007/s11606-014-2917-7
10. S. Dharssi, D. Wong-Rieger, M. Harold, S. Terry, Review of 11
national policies for rare diseases in the context of key patient
needs. Orphanet J. Rare Dis. 12, 63 (2017). https://doi.org/10.
1186/s13023-017-0618-0
11. J. Słowikowska-Hilczer, A.L. Hirschberg, H. Claahsen-van der
Grinten, N. Reisch, C. Bouvattier, U. Thyen, P. Cohen Kettenis,
R. Roehle, B. Köhler, A. Nordenström,dsd-LIFE Group, Fertility
outcome and information on fertility issues in individuals with
different forms of disorders of sex development: findings from the
dsd-LIFE study. Fertil. Steril. 108, 822–831 (2017). https://doi.
org/10.1016/j.fertnstert.2017.08.013
12. S.E. Preves. Intersex and Identity. The Contested Self. (Rutgers
University Press, New Brunswick, New Jersey, London, 2003)
13. A.C. Lossie, J. Green, Building trust: the history and ongoing
relationships amongst DSD clinicians, researchers, and patient
advocacy groups. Horm. Metab. Res. 47, 344–350 (2015). https://
doi.org/10.1055/s-0035-1548793
14. L. Zeeman, A. Aranda, A systematic review of the health and
healthcare inequalities for people with intersex variance. Int. J.
Environ. Res. Public Health 17, 1–18 (2020). https://doi.org/10.
3390/ijerph17186533
15. U. Lampalzer, P. Briken, K. Schweizer, Dealing with uncertainty
and lack of knowledge in diverse sex development: controversies
on early surgery and questions of consent. Sex. Med. 8, 472–489
(2020). https://doi.org/10.1016/j.esxm.2020.03.002
16. P.A. Lee, C.P. Houk, The role of support groups, advocacy groups,
and other interested parties in improving the care of patients with
congenital adrenal hyperplasia: pleas and warnings. Int. J. Pediatr.
Endocrinol. (2010). https://doi.org/10.1155/2010/563640
17. Unicef, Convention on the Rights of the Child, Assembly reso-
lution 44/25. (1990). https://www.unicef.org/child-rights-
convention/convention-text#. Accessed 26 Oct 2020
18. European Parliament, The rights of intersex people, 2018/2878
(RSP). (2018) https://www.europarl.europa.eu/doceo/document/
TA-8-2019-0128_EN.pdf. Accessed 26 Oct 2020




Endocrine (2021) 71:675–680 679
20. C. Wiesemann, S. Ude-Koeller, G.H.G. Sinnecker, U. Thyen,
Ethical principles and recommendations for the medical man-
agement of differences of sex development (DSD)/intersex in
children and adolescents. Eur. J. Pediatr. 169, 671–679 (2010).
https://doi.org/10.1007/s00431-009-1086-x
21. Regulation inserted by the Act on the Amendment of the Infor-
mation to be Entered in the Birth Register of 18 December 2018
(Federal Law Gazette (BGBl.) I p. 2635), entered into force on 22
December 2018). https://www.gesetze-im-internet.de/pstg/__45b.
html




23. C. Flück, A. Nordenström, S.F. Ahmed, S.R. Ali, M. Berra, J.
Hall, B. Köhler, V. Pasterski, R. Robeva, K. Schweizer, A.
Springer, P. Westerveld, O. Hiort, M. Cools, Standardised data
collection for clinical follow-up and assessment of outcomes in
differences of sex development (DSD): recommendations from the
COST action DSDnet. Eur. J. Endocrinol. 181, 545–564 (2019).
https://doi.org/10.1530/EJE-19-0363
24. M. Cools, A. Nordenström, R. Robeva, J. Hall, P. Westerveld, C.
Flück, B. Köhler, M. Berra, A. Springer, K. Schweizer, V. Pas-
terski, COST Action BM1303 working group 1: Caring for indi-
viduals with a difference of sex development (DSD): a Consensus
Statement. Nat. Rev. Endocrinol. 14, 415–429 (2018). https://doi.
org/10.1038/s41574-018-0010-8
25. A. Kohlschütter, H. van den Bussche, Early diagnosis of a rare
disease in children through better communication between par-
ents, physicians and academic centers. Z. Evid. Fortbild. Qual.
Gesundhwes. 141–142, 18–23 (2019). https://doi.org/10.1016/j.
zefq.2019.02.008
26. H. Graessner, F. Scha ̈fer, M. Scarpa, T.O.F. Wagner, European
reference networks: consequences for healthcare in Germany.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
60, 537–541 (2017). https://doi.org/10.1007/s00103-017-2533-x
27. S.R. Ali, J. Bryce, M. Cools, M. Korbonits, J.G. Beun, D. Tar-
uscio, T. Danne, M. Dattani, O.M. Dekkers, A. Linglart, I.
Netchine, A. Nordenstrom, A. Patocs, L. Persani, N. Reisch, A.
Smyth, Z. Sumnik, W.E. Visser, O. Hiort, A.M. Pereira, S.F.
Ahmed, The current landscape of European registries for rare
endocrine conditions. Eur. J. Endocrinol. 180, 89–98 (2019).
https://doi.org/10.1530/EJE-18-0861
28. T. Kötter, E. Blozik, M: Scherer, Methods for the guideline-based
development of quality indicators—a systematic review. Imple-
ment. Sci. 7, 21 (2012). https://doi.org/10.1186/1748-5908-7-21
29. U. Thyen, T. Ittermann, S. Flessa, H. Muehlan, W. Birnbaum, M.
Rapp, L. Marshall, M. Szarras-Capnik, C. Bouvattier, B.P.C.
Kreukels, A. Nordenstroem, R. Roehle, B. Koehler,dsd-LIFE
Group, Quality of health care in adolescents and adults with dis-
orders/differences of sex development (DSD) in six European
countries (dsd-LIFE). BMC Health Serv. Res. 18, 527 (2018).
https://doi.org/10.1186/s12913-018-3342-0
30. A. Donabedian, Evaluating the quality of medical care. Milbank
Mem. Fund. Q 44, 166–206 (1966)
31. A. Donabedian, The Lichfield Lecture. Quality assurance in health
care: consumers’ role. Qual. Health Care 1, 247–251 (1992)
32. S. Rode, V. Ries, T. Petzold, U. Buch, F. Untersweg, B. Fischer,
Requirements and application guide for the use of quality indi-
cators in medical care: results of a systematic review. Gesund-
heitswesen (2016). https://doi.org/10.1055/s-0042-102347
33. C.C. Attkisson, R. Zwick, The client satisfaction questionnaire.
Psychometric properties and correlations with service utilization and
psychotherapy outome. Eval. Program Plann. 5, 233–237 (1982)
34. S. Schmidt, U. Thyen, J. Chaplin, E. Mueller-Godeffroy, Cross-
cultural development of a child health care questionnaire on
satisfaction, utilization, and needs. Ambul. Pediatr. 7, 374–382
(2007). https://doi.org/10.1016/j.ambp.2007.04.007
35. S. Schmidt, U. Thyen, C. Herrmann-Garitz, F. Bomba, H.
Muehlan, The Youth Health Care measure-satisfaction, utilization,
and needs (YHC- SUN)-development of a self-report version of
the Child Health Care (CHC-SUN) proxy-measure. BMC Health
Serv. Res. 16, 189 (2016). https://doi.org/10.1186/s12913-016-
1419-1
36. B.L. Ingram, R.S. Chung, Client satisfaction data and quality
improvement planning in managed mental health care organiza-
tions. Health Care Manag. Rev. 22, 40–52 (1997)
37. A. Lux, S. Kropf, E. Kleinemeier, M. Jürgensen, U. Thyen,The
DSD Network Working Group, Clinical evaluation study of the
German network of disorders of sex development (DSD)/inter-
sexuality: study design, description of the study population, and
data quality. BMC Public Health 21, 110 (2009). https://doi.org/
10.1186/1471-2458-9-110
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